About PER
Percheron Therapeutics (PER), formerly Antisense Therapeutics, develops oncology and rare-disease therapies, led by HMBD-002, a monoclonal antibody targeting the VISTA checkpoint.
All News for PER
No news articles found for PER yet.
PER
Health Care Sector News